The FDA has approved Twynsta (telmisartan/amlodipine tablets, from Boehringer Ingelheim) for the treatment of hypertension alone or in combination with other antihypertensives, or as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals. This approval was based on data from one placebo-controlled and two active-controlled trials involving 3,505 patients with stage 1 or stage 2 hypertension. Results demonstrated that Twynsta was generally well-tolerated and provided significant blood pressure reductions in a variety of hypertensive patient populations compared with placebo or monotherapy. (left out period)
Twynsta is expected to be available in November 2009 in 40mg/5mg, 40mg/10mg, 80mg/5mg, and 80mg/10mg dosage strengths.
For more information call (800) 243-0127 or visit us.boehringer-ingelheim.com.